

- H, Togawa H, Hashimura Y, Kaito H, Sako M, Iijima K, Yoshikawa N. Validity of the Oxford classification of IgA nephropathy in children. *Pediatr Nephrol*. 2012;27:783-92
- 13) 中西浩一, 吉川徳茂: 織毛病 (Ciliopathy). *日本小児腎臓病学会雑誌* 2012;25(2):127-131
- 14) 中西浩一, 吉川徳茂. 遺伝性腎炎(Alport 症候群). *小児疾患の診断治療基準 第4版 小児内科* 2012;44 増刊号:630-631
- 15) 中西浩一, 吉川徳茂 慢性糸球体腎炎 18章 腎・泌尿器・生殖器疾患 総編集 遠藤文夫 「小児科診断・治療ガイド」 中山書店 2012;673-679
- 16) 中西浩一, 吉川徳茂 多発性嚢胞腎 (小児) 編集 「腎と透析」編集委員会 「腎疾患治療マニュアル 2012-2013」 東京医学社 2012;445-449
- 17) 中西浩一, 吉川徳茂: ARPKD の基礎と臨床-最新の知見 特集: 多発性嚢胞腎-最新の知見と今後の課題. *日本腎臓学会誌* 2012;54(4):534-537
- 18) 戸川寛子, 中西浩一, 吉川徳茂: 髄質嚢胞腎. 腎臓症候群(第2版)-その他の腎臓疾患を含めて-別冊日本臨床 新領域別症候群シリーズ 17:600-602, 2012.
- 19) 島友子, 中西浩一, 吉川徳茂 【小児の診療手技 100】腎生検 小児科診療(0386-9806)75 巻増刊 Page286-290(2012.04)
- 20) 中西浩一, 吉川徳茂, 服部元史: 常染色体劣性多発性嚢胞腎-疫学と臨床. 特集: 多発性嚢胞腎, 腎臓 2012;34(3):194-200
- 21) 中西浩一, 吉川徳茂 遺伝子診断の臨床応用-ネフローゼ症候群 小児内科 クローズアップ腎泌尿器 44(2):210-215, 2012
- 22) 中西浩一 遺伝性糸球体疾患 編集 日本小児腎臓病学会 小児腎臓病学 診断と治療社 2012;210-214
2. 学会発表
- 1) Ishimori S, Kaito H, Ohtsubo H, Hashimoto F, Ninchoji T, Kamioka I, Shima Y, Hamahira K, Nakanishi K, Tanaka R, Yoshikawa N, Iijima K: Clinicopathological characteristics and kidney outcome of childhood-onset lupus nephritis with acute kidney injury: from the multicenter study in Japan. The 45th ESPN Annual Meeting, September 6th – 8th 2012, Krakow, Poland
- 2) Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Ishimori S, Kaito H, Tanaka R, Iijima K, Yoshikawa N. Histological Predictors of Treatment Efficacy in Severe Childhood IgA Nephropathy (IgAN): Validation of the Oxford Classification of IgAN (Ox C). 45th Annual Meeting of the American Society of Nephrology, Nov.1-Nov.4, 2012 in San Diego, USA. *JASN* 23:193A
- 3) Hama T, Nakanishi K, Mukaiyama H, Togawa H, Shima Y, Miyajima M, Takahashi H, Nagao S, Iijima K, Yoshikawa N. Possible Contribution of Fibrocytes to Renal Fibrosis in Cpk Mouse, a Model of ARPKD. 45th Annual Meeting of the American Society of Nephrology, Nov.1-Nov.4, 2012 in San Diego, USA. *JASN* 23:596A
- 4) Ishikura K, Uemura O, Ito S, Wada N, Hattori M, Ohashi Y, Hamasaki Y, Tanaka R, Nakanishi K, Kaneko T, Honda M: The Pediatric-CKD Study Group in Japan. Progression to End-Stage Kidney Disease in Children with CKD: A Nation- Wide Cohort Study in Japan. 45th Annual Meeting of the American Society of Nephrology, Nov.1-Nov.4, 2012 in San Diego, USA. *JASN* 23:684A
- 5) Hashimura Y, Nozu K, Kaito H, Ohtsubo H, Hashimoto F, Ishimori S, Ninchoji T, Morisada N, Nakanishi K, Yoshikawa N, Iijima K. Genetical and Clinical Aspects of X-Linked Alport Syndrome in Males with Positive Staining of the alpha5(IV) Chain. 45th Annual Meeting of the American Society of Nephrology, Nov.1-Nov.4,

2012 in San Diego, USA. JASN 23:33A

6) Ninchoji T, Kaito H, Nozu K, Nakanishi K, Yoshikawa N, Iijima K. Clinical Characteristics and Mutational Pattern of Genetically-Proven Gitelman's Syndrome. 45th Annual Meeting of the American Society of Nephrology, Nov.1-Nov.4, 2012 in San Diego, USA. JASN 23:437A

7) 中西浩一：エビデンスに基づく小児腎臓病治療を目指して～JSKDCの歩み～ 第5回宮城小児腎・泌尿器研究会 2012年5月25日 仙台

8) 中西浩一：エビデンスに基づく小児腎臓病治療を目指して 第52回新潟腎臓懇話会 2012年6月14日 新潟

9) 中西浩一：織毛病 プロフェッショナル-5 第47回日本小児腎臓病学会学術集会 2012年6月29～30日 東京

10) 中西浩一：日本医学会「医療における遺伝学的検査・診断に関するガイドライン」について 学会主導企画2 第47回日本小児腎臓病学会学術集会 2012年6月29～30日 東京

11) 中西浩一：ARPKDの病態・遺伝子診断 シンポジウム2 小児嚢胞性腎疾患の病因・病態の解明と診断・治療の進歩 座長兼任 第34回日本小児腎不全学会学術集会 2012年9月13～14日 洲本（兵庫県・淡路島）

12) 中西浩一：エビデンスに基づく小児腎臓病治療 Chiba Pediatric Nephrology Forum 2012年10月18日 千葉

13) 中西浩一：遺伝性ネフローゼ症候群と多発性嚢胞腎 第22回北海道小児腎臓病研究会 2012年10月20日 札幌

14) 中西浩一：アルポート症候群と多発性嚢胞腎 第11回弘前小児腎疾患フォーラム 2012年10月26日 弘前

2. 実用新案登録

該当無し.

3. その他

該当無し.

G. 知的財産権の出願・登録状況

1. 特許取得

該当無し.

Ⅲ. 研究成果の刊行に関する 一覧表

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
上村 治	小児科におけるCKD はどのように捉えるとい いのでしょうか？	今井 圓裕	CKD 診 療 ガイ ド 2012 Q&A	診断と治 療社	東京	2012	20-22
上村 治	小児の CKD 患 者の動向はどの ようになっていますか？	今井 圓裕	CKD 診 療 ガイ ド 2012 Q&A	診断と治 療社	東京	2012	44-45

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ishikura K, Uemura O, Ito S, Wada N, Hattori M, Ohashi Y, Hamasaki Y, Tanaka R, Nakanishi K, Kaneko T, Honda M	Pre-dialysis chronic kidney disease in children: results of a nationwide survey in Japan	Nephrology Dialysis Transplantation	in press	in press	in press
Uemura O, Ushijima K, Nagai T, Yamada T, Yamakawa S, Hibi Y, Hayakawa H, Nabeta Y, Shinkai Y, Koike K, Kuwabara M	Measurements of serum cystatin C concentrations underestimate renal dysfunction in pediatric patients with chronic kidney disease	Clinical and Experimental Nephrology	15(4)	535-538	2011

Uemura O, Honda M, Matsuyama T, Ishikura K, Hataya H, Nagai T, Ikezumi Y, Fujita N, Ito S, Iijima K	Is the new Schwartz equation derived from serum creatinine and body length suitable for evaluation of renal function in Japanese children?	European Journal of Pediatrics	171(9)	1401-1404	2012
Ikezumi Y, Honda M, Matsuyama T, Ishikura K, Hataya H, Yata N, Nagai T, Fujita N, Ito S, Iijima K, Kaneko T, Uemura O	Establishment of a normal reference value for serum β_2 microglobulin in Japanese children: reevaluation of its clinical usefulness	Clinical and Experimental Nephrology	17(1)	99-105	2013
Yata N, Uemura O, Honda M, Matsuyama T, Ishikura K, Hataya H, Nagai T, Ikezumi Y, Fujita N, Ito S, Iijima K, Saito M, Kaneko T, Kitagawa T.	Reference ranges for serum cystatin C measurements in Japanese children by using 4 automated assays	Clinical and Experimental Nephrology	Epub ahead of print	Epub ahead of print	2013; [Epub ahead of print]
上村 治	小児における慢性 腎臓病対策	日本小児科学会 雑誌	115 卷 11 号	1713-1726	2011

IV. 研究成果の刊行物・別刷

Q10

小児科におけるCKDはどのように捉えるといいのでしょうか？

A 小児のCKDの定義は基本的に成人と同様です。ただし、GFR区分は2歳以上には使えますが、腎機能が未成熟の2歳未満には使えないことになっています。2歳未満に対しては各年月齢の正常者の腎機能の中央値を基準にして、75%、50%、25%、12.5%をステージの境界値と考えてわが国では分類しています。

小児CKDの定義

小児のCKDの定義上の最大の問題点は腎機能の成熟にあり、GFRは新生児期に成人の20～30%程度からはじまり、2歳までに成人値に達する。そのために、小児と思春期のCKDについての臨床診療ガイドライン¹⁾では、5段階のCKDステージ分類の適応は2歳以上に限るべきとした。しかし、2歳未満の乳幼児についても同様に分類できることが望ましい。KDOQIのCKDについての臨床診療ガイドラインでは²⁾、GFR 60 mL/分/1.73 m²を loss of half (腎機能が正常の半分)と考えていることを利用して、2歳未満の乳幼児についても正常者の腎機能の代表値(中央値または平均値)の半分以上を切ればステージ3(1/4を切ればステージ4, 1/8を切ればステージ5)と考えて定義可能であると考えている。このようにして、日本人小児の血清クレアチニン基準値³⁾から作成したCKDステージ分類が表1～3である。

◎小児CKDのフォローアップ

ところで、小児CKD対策の意義はどこにあるであろうか。CKDの考え方は疾患特異的ではなく、早期診断と疾患非特異的な介入(または非介入)により患者に有意義な人生を送ってもらうという視点が重要である。以下に、網羅的な視点から成人と異なり小児に特別に配慮しておかなくてはならない項目を列挙する。

- 小児CKDステージG3以上の多くを占める先天性腎尿路疾患(CAKUT)に対する小児泌尿器科医との協力。
Q20表1に示すようにCAKUTが62%を占める。
- 腎臓病学校検診後のフォローの重要性、特に小児腎臓専門医の紹介基準。
小児腎臓専門医の紹介基準はQ40表参照。
- 体位性蛋白尿や良性家族性血尿などの軽症疾患の確実な診断とインフォームドコンセント検診で注意すべき1つの点は、本来は治療の必要のない軽症の疾患も発見されてしまうことである。レッテルを貼られて患者家族が不安になるようでは検診の弊害となる。きちんと心配のない病気であることを説明し不要な生活制限をかけない。
- 進行したCKDの様々な合併症(図1)を考慮したフォローアップ(特に成長発達への配慮)。
進行したCKDは全身病であり、精神的・社会的介入も含めて全人的な配慮が必要である。
- 運動制限、食事制限の弊害と、証拠のなさ。
運動制限や成長に影響のない蛋白制限は、小児CKD患者の腎保護作用についての証拠は

表1 2歳未満(男性および女性)血清クレアチニン値とCKDステージ

年齢	ステージ G3	ステージ G4	ステージ G5
3~5か月	0.41~0.80	0.81~1.60	1.61~
6~8か月	0.45~0.88	0.89~1.76	1.77~
9~11か月	0.45~0.88	0.89~1.76	1.77~
1歳	0.47~0.92	0.93~1.84	1.85~

(日本小児腎臓病学会・小児CKD対策委員会)

表2 2歳以上12歳未満(男性および女性)血清クレアチニン値とCKDステージ

年齢	ステージ G3	ステージ G4	ステージ G5
GFR (mL分/1.73 m ²)	60未満 30以上	30未満 15以上	15未満
2歳	0.49~0.96	0.97~1.92	1.93~
3歳	0.55~1.08	1.09~2.16	2.17~
4歳	0.61~1.20	1.21~2.40	2.41~
5歳	0.69~1.36	1.37~2.72	2.73~
6歳	0.69~1.36	1.37~2.72	2.73~
7歳	0.75~1.48	1.49~2.96	2.97~
8歳	0.81~1.60	1.61~3.20	3.21~
9歳	0.83~1.64	1.65~3.28	3.29~
10歳	0.83~1.64	1.65~3.28	3.29~
11歳	0.91~1.80	1.81~3.60	3.61~

(日本小児腎臓病学会・小児CKD対策委員会)

表3 12歳以上16歳未満(男女別)血清クレアチニン値とCKDステージ

男児

年齢	ステージ G3	ステージ G4	ステージ G5
GFR (mL分/1.73 m ²)	60未満 30以上	30未満 15以上	15未満
12歳	1.07~2.12	2.13~4.24	4.25~
13歳	1.19~2.36	2.37~4.72	4.73~
14歳	1.31~2.60	2.61~5.20	5.21~
15歳	1.37~2.72	2.73~5.44	5.45~
16歳	1.47~2.92	2.93~5.84	5.85~

女児

年齢	ステージ G3	ステージ G4	ステージ G5
GFR (mL分/1.73 m ²)	60未満 30以上	30未満 15以上	15未満
12歳	1.05~2.08	2.09~4.16	4.17~
13歳	1.07~2.12	2.13~4.24	4.25~
14歳	1.17~2.32	2.33~4.64	4.65~
15歳	1.13~2.24	2.25~4.48	4.49~
16歳	1.19~2.36	2.37~4.72	4.73~

(日本小児腎臓病学会・小児CKD対策委員会)




図1 小児慢性腎不全の合併症

* Karlberg は、小児の縦断的成長を数学的にモデル化、Infancy(乳幼児期)・Childhood(小児期)・Puberty(思春期)の3つの成分に分ける ICP モデルを提唱、小児期は成長ホルモン、思春期には性ホルモンが重要であるが、乳幼児期の成長については栄養が重要であるとした。

ない。

- 小児の血圧の基準値の年齢による違い。
基準値は Q71 表参照。

- 移行(transition)への配慮。

移行とは、慢性疾患を持った思春期や若年成人を小児医療施設から成人医療施設に向けて目的をもって計画的に移動させることをいう。移行の失敗は患者の治療不適応に繋がり不可逆的障害を残すこともあるので、そのプログラムは疾患の始まりから前もって計画的に始められる必要がある。子ども達が自尊心を確立し自己決定できる自立/自律した大人になることを目標に、専門的な医療やケアを意図的・計画的に提供しなくてはならない。

- 小児に対する ACE-I(アンジオテンシン変換酵素阻害薬)や ARB (アンジオテンシン受容体拮抗薬)の腎保護効果の有効性の有無。
有効である可能性は高いが証拠はまだない。

文献

- 1) Hogg RJ, et al : National Kidney Foundation's Kidney Disease Outcomes Quality Initiative. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents : evaluation, classification, and stratification. *Pediatrics* 2003 ; 111 : 1416-1421
- 2) National Kidney Foundation : K/DOQI clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification. *Am J Kidney Dis* 2002 ; 39 : S1-266
- 3) Uemura O, et al. : Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study. *Clin Exp Nephrol* 2011 ; 15 : 694-699

(上村 治)

Q20

小児のCKD患者の動向はどのようになっていますか？

A 日本の小児CKD患者の疫学研究により、生後3か月～15歳の日本の小児における透析前のCKDステージ3～5の有病率が29.5例/100万であることがわかりました。実際の日本全国の症例数は447例(回収率77.7%)で、そのうち405例(90.6%)は非糸球体疾患で、しかも278例(68.6%)は先天性腎尿路疾患(CAKUT)でした。

 日本の小児CKD患者の疫学研究

小児CKDの疫学研究は、アジアでは初めてで、これまでは西欧諸国の報告¹⁻³⁾のみであった。これらの研究では、血清クレアチニン値による推算GFR(eGFR)によってステージ分類されており、古いシュワルツの式がGFRを推定するために使用されている。しかし、最近血清クレアチニン(Cr)測定の多くがヤッフエ法から酵素法を使用するようになったので、シュワルツの式は新たに作り変えられた⁴⁾。しかし、これらは欧米人の式であり、日本人の小児でシュワルツの式を使用する場合、GFRを過大評価する可能性があり、また12歳以上に同一の式を使うことにも問題がある⁵⁾。

日本人小児に固有のeGFRはまだなく(ほぼ完成しているが疫学研究をやる時点ではまだなかった)、われわれが独自に確立した血清Cr基準値を利用して腎機能を評価しCKDステージ分類を行った(Q3参照)。小児のCKDの定義上の最大の問題点は、腎機能の成熟にある。GFRは新生児期に成人の20～30%程度からはじまり、2歳までに成人値に達すると考えられている^{6,7)}。小児と思春CKDについての臨床診療ガイドライン⁸⁾が2003年にNKF KDOQIから示され、成人同様に定義された。このガイドラインでは、腎機能の生理的未成熟の理由から5段階のCKDステージ分類の適応は2歳以上に限るべきとしている。しかし、2歳未満の乳幼児についても同様に分類できることが望ましい。KDOQIのCKDについての臨床診療ガイドラインでは⁹⁾、GFR 60 mL/分/1.73 m²をloss of half(腎機能が正常の半分)と考えることが明らかである。本来の理念を利用して2歳未満の乳幼児についても分類すべきであり、正常者の腎機能の代表値(中央値または平均値)の半분을切ればステージ3(1/4を切ればステージ4、1/8を切ればステージ5)と考えて定義可能であるとした。

この方法で日本人小児のCKDを診断しステージ分類した。生後3か月から15歳の日本人小児のCKDは、調査回収率77.7%で総数447例であり、そのうち405例(90.6%)は非糸球体疾患で、しかも278例(68.6%)は先天性腎尿路疾患(CAKUT)であった。原疾患の詳細な内訳は表1の通りである。つまり、腎機能が半分以下の小児CKD患者の多くはCAKUTを原因としており、いわゆる慢性糸球体腎炎はごく少数であった。また、全体の70.7%はステージ3、23.3%はステージ4、6.0%はステージ5であった。

またこの疫学研究で、透析前のCKDステージ3～5の有病率は29.5例/100万日本人小児であると推定された。これは、ItalKid¹⁾とREPIR II Projects²⁾(それぞれ74.7例、71.1例/100

表1 3か月から15歳の日本人小児のCKDステージ3～5患者447例の原疾患(代表的なものに限る)

疾患	非糸球体性	糸球体性	分類不能
	N = 405(90.6%)	N = 38(8.5%)	N = 4(0.9%)
先天性腎尿路疾患	278	—	—
周産期障害	37	—	—
多発性嚢胞腎	21	—	—
ネフロン癆	20	—	—
アルポート症候群	—	10	—
巣状糸球体硬化	—	9	—
慢性糸球体腎炎	—	8	—
先天性ネフローゼ症候群	—	3	—

(日本小児腎臓病学会・小児CKD対策委員会)

万小児)で報告されたものより低かった。ただし対象が、ItalkidはeGFR < 75 mL/分/1.73 m²の20歳未満の小児で、REPIR IIは19歳未満の小児CKDステージ2～5(ステージ2が42%含まれる)であるという点で異なり、REPIR IIでCKDステージ3～5を計算すると有病率は41.2例/100万小児となることもあわせて考えると、大きな違いはないように思える。

日本の小児CKD疫学研究では、糸球体疾患は非常に少なく、なかでも慢性糸球体腎炎はわずか8例のみであった。また別に1998年に実行された小児ESKD患者の日本のレジストリにおいて、IgA腎症はわずか3%であった¹⁰⁾。これらの慢性糸球体腎炎がCKDやESKDの原疾患として少ないのは1974年にはじまった腎臓病学校検診の効果であるとも考えられる。今後はCAKUTに対する対策の充実が望まれる。

文献

- 1) Ardissino G, et al. : Epidemiology of chronic renal failure in children : data from the Italkid project. *Pediatrics* 2003 ; 111 : e382-387
- 2) Areses Trapote R, et al. : Epidemiology of chronic kidney disease in Spanish pediatric population. REPIR II Project. *Nefrologia* 2010 ; 30 : 508-517
- 3) Furth SL, et al. : Design and methods of the Chronic Kidney Disease in Children (CKD) prospective cohort study. *Clin J Am Soc Nephrol* 2006 ; 1 : 1006-1015
- 4) Schwartz GJ, et al. : The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. *Pediatr Clin North Am* 1987 ; 34 : 571-590
- 5) Uemura O, et al. : Is the new Schwartz equation derived from serum creatinine and body length suitable for evaluation of renal function in Japanese children? *Eur J Pediatr* 2012 ; 171 : 1401-1404
- 6) Heilbron DC, et al. : Expressing glomerular filtration rate in children. *Pediatr Nephrol* 1991 ; 5 : 5-11
- 7) Coulthard MG. Maturation of glomerular filtration in preterm and mature babies. *Early Hum Dev* 1985 ; 11 : 281-292
- 8) Hogg RJ, et al. : National Kidney Foundation's Kidney Disease Outcomes Quality Initiative. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents : evaluation, classification, and stratification. *Pediatrics* 2003 ; 111 : 1416-1421
- 9) National Kidney Foundation : K/DOQI clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification. *Am J Kidney Dis* 2002 ; 39 : S1-266
- 10) Hattori S, et al. : The 1998 report of the Japanese National Registry data on pediatric end-stage renal disease patients. *Pediatr Nephrol* 2002 ; 17 : 456-461

(上村 治)

Original Article

Pre-dialysis chronic kidney disease in children: results of a nationwide survey in Japan

Q1 Kenji Ishikura¹, Osamu Uemura², Shuichi Ito³, Naohiro Wada⁴, Motoshi Hattori⁵, Yasuo Ohashi⁶,
Yuko Hamasaki⁷, Ryojiro Tanaka⁸, Koichi Nakanishi⁹, Tetsuji Kaneko¹⁰ and Masataka Honda¹
5 on behalf of The Pediatric CKD Study Group in Japan in conjunction with the Committee
of Measures for Pediatric CKD of the Japanese Society of Pediatric Nephrology

¹Department of Nephrology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan, ²Department of Pediatric Nephrology, Aichi Children's Health and Medical Center, Aichi, Japan, ³Department of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan, ⁴Department of Pediatric Nephrology, Shizuoka Children's Hospital, Shizuoka, Japan, ⁵Department of Pediatric Nephrology, Tokyo Women's Medical University, Tokyo, Japan, ⁶Department of Biostatistics, School of Public Health, The University of Tokyo, Tokyo, Japan, ⁷Department of Pediatric Nephrology, Toho University Omori Medical Center, Tokyo, Japan, ⁸Department of Nephrology, Hyogo Prefectural Children's Hospital, Hyogo, Japan, ⁹Department of Pediatrics, Wakayama Medical University, Wakayama, Japan and ¹⁰Department of Clinical Trial, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan

15 Correspondence and offprint requests to: Kenji Ishikura; E-mail: kenzo@ii.e-mansion.com

Abstract

Background. Chronic kidney disease (CKD) in children is a progressive and intractable condition that may severely impair the child's growth, development and quality of life. Epidemiological information on pediatric CKD, particularly in Asians, is scant.

Methods. We conducted a nationwide survey of Japanese children aged 3 months to 15 years with pre-dialysis CKD to examine the prevalence of pediatric CKD in Japan. CKD was classified according to newly established criteria derived from reference serum creatinine levels in Japanese children. Surveys were sent to 1190 institutions across Japan to report on cases of pediatric CKD managed as of 1 April 2010.

Results. A total of 925 institutions (77.7%) responded. Information on 447 children was collected. When subdivided according to our diagnostic criteria, 70.5% of children had stage 3 CKD, 23.9% stage 4 and 5.6% stage 5. The estimated prevalence of Japanese children with CKD was 2.95 cases/100 000 children. Of 407 CKD cases with non-glomerular disease, 278 (68.3%) had congenital anomalies of the kidney and urinary tract (CAKUT). The newly established criteria showed good validity compared with existing criteria, including the abbreviated Schwartz equation.

Conclusions. Findings from the first nationwide survey of pre-dialysis CKD in Asian children indicate that the prevalence of stage 3–5 CKD in children in Japan aged 3 months to 15 years is 2.95 cases/100 000 children. Most children with CKD presented with non-glomerular disease, most frequently CAKUT. Improved management of CAKUT, including renoprotective treatment and urological intervention, is required.

Keywords: adolescent; child; creatinine; epidemiology; Japan; kidney diseases; preschool

Q2

Introduction

50

Chronic kidney disease (CKD) in children is a progressive and intractable condition, with devastating effects on the patient's growth, development and quality of life. If left untreated, pediatric CKD eventually progresses to end-stage renal disease (ESRD), which requires long-term dialysis or repeated renal transplantation. The mortality rate for children with ESRD on dialysis is estimated to be 30–150 times that of the general pediatric population [1, 2]. Therefore, it is particularly important to detect CKD as early as possible, possibly by applying simple but accurate screening of at-risk children. Early identification of these children can then allow the physician to promptly introduce appropriate therapy that can prevent or slow the progression of CKD to ESRD, reducing the incidence of stage 5 CKD and to control comorbidity.

55

60

65

Epidemiological information on CKD in children is currently limited, but this sort of information is necessary to understand the extent of the problem, to identify populations at risk and to determine the efficacy of current therapeutic interventions. Although several studies have described the epidemiology of pre-dialysis CKD in children in Western countries [3–10], very few have focused on Asian children. It is also important to consider that there may be differences in the epidemiology of CKD among countries that may be due to racial differences, variations in screening methods among medical

70

75

Table 1. Diagnostic criteria for stage 3–5 chronic kidney disease based on reference serum creatinine levels (mg/dL) of Japanese children aged 3 months to 11 years

Age	2.5th percentile	50th percentile	97.5th percentile	CKD stage 3	CKD stage 4	CKD stage 5
<2 years						
3–5 months	0.14	0.20	0.26	0.41–0.80	0.81–1.60	≥1.61
6–8 months	0.14	0.22	0.31	0.43–0.84	0.85–1.68	≥1.69
9–11 months	0.14	0.22	0.34	0.47–0.92	0.93–1.84	≥1.85
1 year	0.16	0.23	0.24	0.47–0.92	0.93–1.84	≥1.85
2–12 (years)						
2	0.17	0.24	0.37	0.49–0.96	0.97–1.92	≥1.93
3	0.21	0.27	0.37	0.55–1.08	1.09–2.16	≥2.17
4	0.20	0.30	0.40	0.61–1.20	1.21–2.40	≥2.41
5	0.25	0.34	0.45	0.69–1.36	1.37–2.72	≥2.73
6	0.25	0.34	0.48	0.69–1.36	1.37–2.72	≥2.73
7	0.28	0.37	0.49	0.75–1.48	1.49–2.96	≥2.97
8	0.29	0.40	0.53	0.81–1.60	1.61–3.20	≥3.21
9	0.34	0.41	0.51	0.83–1.64	1.65–3.28	≥3.29
10	0.30	0.41	0.57	0.81–1.60	1.61–3.20	≥3.21
11	0.35	0.45	0.58	0.91–1.80	1.81–3.60	≥3.61

Values were matched for age alone. Values for the 2.5, 50 and 97.5th percentiles are as presented in Uemura *et al.* [11]. Table reproduced with the permission of the Japanese Society of Nephrology.

institutions and differences in in-school screening programs. To address this problem of limited information in Asian children and to assist subsequent population-based surveys, we previously determined reference serum creatinine (SCr) levels in Japanese children [11].

Our first objective in this study was to determine the prevalence of pre-dialysis CKD in a cross-sectional, nationwide survey of Japanese children aged 3 months to 15 years with pre-dialysis CKD. Stage 3–5 CKD was detected and classified using newly established criteria derived from normal SCr levels of age- and sex-matched Japanese children. Because CKD is defined as a GFR of <60 mL/min/1.73 m² (less than half of normal GFR) in the Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines [12, 13] and the Kidney Disease: Improving Global Outcomes (KDIGO) position statement [14] (corresponding to stage 3 or worse), we focused on patients meeting this criterion and who had not yet received dialysis or renal transplantation. Our second objective was to determine the etiology of CKD as well as the method of detection of CKD and the treatment modalities used in routine clinical practice in Japan.

Materials and methods

Establishment of new diagnostic criteria for CKD in children

The new diagnostic criteria for stage 3–5 CKD were based on previously established reference SCr levels of Japanese children [11]. Briefly, in that study, body length and SCr levels were determined in 1151 healthy children aged 1 month to 18 years who presented at the facilities of the Committee of Measures for Pediatric CKD and Tokyo Health Service Association between 2008 and 2009. Reference intervals of SCr against age were calculated in children aged 3 months to 11 years, and those against age and sex were calculated in children aged 12–16 years.

According to the K/DOQI guidelines [12, 13] and KDIGO position statement [14] for CKD, stage 3–5 CKD was classified as GFR 30–59, 15–29 and <15 mL/min/1.73 m², respectively (<1/2, <1/4 and 1/8 of normal GFR, respectively), whereas normal GFR was considered to be ~120 mL/min/1.73 m². Given that the GFR is inversely proportional to SCr for a given body type and age [15], we classified stage 3–5 CKD as SCr more than twice, four times and eight times, the median normal SCr

Table 2. Diagnostic criteria for stage 3–5 chronic kidney disease based on reference serum creatinine levels (mg/dL) of Japanese male and female children aged 12–15 years

	2.5th percentile	50th percentile	97.5th percentile	CKD stage 3	CKD stage 4	CKD stage 5
Males (years)						
12	0.40	0.53	0.61	1.07–2.12	2.13–4.24	≥4.25
13	0.42	0.59	0.80	1.19–2.36	2.37–4.72	≥4.73
14	0.54	0.65	0.96	1.31–2.60	2.61–5.20	≥5.21
15	0.48	0.68	0.93	1.37–2.72	2.73–5.44	≥5.45
Females (years)						
12	0.40	0.52	0.66	1.05–2.08	2.09–4.16	≥4.17
13	0.41	0.53	0.69	1.07–2.12	2.13–4.24	≥4.25
14	0.46	0.58	0.71	1.17–2.32	2.33–4.64	≥4.65
15	0.47	0.56	0.72	1.13–2.24	2.25–4.48	≥4.49

Values were matched for age and sex. Values for the 2.5, 50 and 97.5th percentiles are as presented in Uemura *et al.* [11]. Table reproduced with the permission of the Japanese Society of Nephrology

levels matched for age alone in children aged 3 months to 11 years (Table 1), or matched for age and sex in children aged 12–16 years (Table 2).

Study design and population

This was a cross-sectional, nationwide, population-based survey conducted by the Pediatric CKD Study Group in Japan in conjunction with the Committee of Measures for Pediatric CKD of the Japanese Society of Pediatric Nephrology (JSPN). Two surveys were sent in August 2010 to a total of 1190 institutions in Japan, including all institutions that are members of the JSPN, all university and children's hospitals and all general hospitals with >200 beds, inviting them to report cases of pediatric CKD that were managed as of 1 April 2010. We selected these types of hospital because children with apparent CKD were usually referred to institutions meeting one of these criteria. The deadlines for the first and second surveys were October 2010 and November 2010, respectively.

The first questionnaire was designed to record the presence and approximate number of children with stage 3–5 CKD in each institution. The second questionnaire recorded data for each case, including age, date of birth, sex, height, SCr level, primary renal diagnosis and associated diseases, method of detection, co-morbidities and prescribed

treatment. For the purpose of this survey, only data recorded within 6 months of 1 April 2010 were included. The patient's age was calculated from the date of birth and the date of each measurement. This questionnaire also recorded information for each institution, including the SCr assay method used and prescribed treatment strategies. The respondents were asked to search their medical records for patients with a confirmed diagnosis of CKD or for patients with an abnormal SCr.

The inclusion criteria were as follows: (i) children with CKD aged 3 months to 15 years at the time of 1 April 2010; (ii) stage 3–5 CKD, as determined by the newly established diagnostic criteria and (iii) no prior treatment with dialysis or renal transplantation. Only cases with renal failure that had lasted for >3 months were included and cases with transient increases in creatinine were excluded.

The study was conducted in accordance with the ethical principles set out in the Declaration of Helsinki, and with the ethical guidelines for epidemiological studies issued by the Ministry of Health, Labour and Welfare in Japan. The study was approved by the JSPN ethics board and a central ethics board (the institution of the Principal Investigator, KI) before study commencement. Because, data were reported retrospectively using patient charts, informed consent was not obtained in accordance with the above guidelines.

Statistical analyses

Estimation of the number of patients with stage 3–5 CKD in Japan from the reported number of patients in our survey was conducted as follows. The estimates were derived as the reported number divided by the response rate. Because the response rate tends to be lower in institutions with fewer patients, simple estimates can overestimate the true prevalence. Therefore, the reported patients were stratified according to institution type (i.e. university hospital, children's hospital and general hospital) and the number of beds (<200, 200–500 and >500), based on the assumption that the response rate is independent of the number of patients in each stratified category [16]. Then, the number of reported patients in each category was divided by the response rate and summed to calculate the total estimated number of patients in Japan. The total estimated number of patients was divided by the size of the population at risk in Japan reported by the Statistics Bureau of the Ministry of Internal Affairs and Communications of Japan (<http://www.stat.go.jp/english/index.htm>) to calculate the prevalence as of 1 April 2010. Weighted κ with 95% confidence interval (CI) was calculated to compare the CKD classification used here with the abbreviated Schwartz equation. All statistical analyses were carried out using SAS system version 9 (SAS Institute, Inc., Cary, NC, USA).

Results

Subject characteristics

A total of 925 of 1190 institutions (77.7%) responded to the first questionnaire. A total of 479 children were identified in the second questionnaire. Of these, 447 children (272 males and 175 females) with stage 3–5 CKD who had not been treated with dialysis/renal transplantation fulfilled the eligibility criteria and were included in this study. Their characteristics are summarized in Table 3. Most of the children (315; 70.5%) had stage 3 CKD, whereas 107 (23.9%) had stage 4 and 25 (5.6%) had stage 5. The number of Japanese children with stage 3–5 CKD was estimated to be 536.5 (95% CI: 493.2–579.8) as of 1 April 2010. On the basis of this, the prevalence of stage 3–5 CKD was calculated to be 2.95 cases/100 000 Japanese children aged 3 months to 15 years. Figure 1 shows the SCr values for males and females according to CKD stage. All of the responding institutions used enzyme immunoassays to determine SCr levels for the assessment of CKD stage; none used other methods, such as the Jaffe method.

Table 3. Patient characteristics according to chronic kidney disease stage

	All subjects	Stage 3	Stage 4	Stage 5
<i>n</i>	447	315	107	25
Age (years)	8.7 ± 4.5	8.7 ± 4.6	8.5 ± 4.3	10.0 ± 4.5
Serum creatinine (mg/dL)	1.6 ± 1.2	1.1 ± 0.4	2.2 ± 0.8	5.3 ± 2.0
Height (cm)	119.8 ± 28.9	121.1 ± 28.7	118.8 ± 27.4	107.8 ± 35.6
Height SDS ^a	-1.6 ± 1.8	-1.3 ± 1.5	-2.2 ± 2	-3.5 ± 3
BUN (mg/dL)	35.6 ± 18.8	28.4 ± 9.8	48.6 ± 18.2	74.9 ± 31.5
CysC (mg/L)	2.1 ± 0.8	1.9 ± 0.5	3.1 ± 1.0	4.1 ± 0.9
eGFR—abbreviated (mL/min/1.73 m ²) ^b	39.5 ± 16	47.2 ± 11.2	22.6 ± 5.5	9.6 ± 3.2
eGFR—complete (mL/min/1.73 m ²) ^c	39.6 ± 12.3	43.7 ± 9.7	24.9 ± 5.3	11.6 ± 4.1

Values are means ± standard deviation.

SDS, standard deviation score; BUN, blood urea nitrogen; CysC, cystatin C.

^aHeight SDS was calculated using data recorded by the Japanese Society for Pediatric Endocrinology in 2000 (http://jspe.umin.jp/ipp_taikaku.htm).

^bDetermined using the abbreviated Schwartz equation.

^cDetermined using the complete Schwartz equation.

Figure 2 shows the frequencies of CKD stage according to the estimated GFR (eGFR) of 412 children in whom height was measured. Stage 3–5 CKD was classified using our diagnostic criteria derived from SCr levels of age- and sex-matched Japanese children, while the eGFR was determined using the abbreviated Schwartz equation, which was recently revised from the original Schwartz equation [17]. This figure also shows the distribution of children classified in each CKD stage determined using both methods. These data indicate that the distribution of CKD stages determined using population-based reference values is comparable with the distribution derived using a method based on the abbreviated Schwartz equation. The weighted κ -value for this comparison was 0.71 (95% CI: 0.65–0.77). For 198 children with cystatin C data, similar distributions were obtained when we compared our new classification with the complete Schwartz equation, which requires cystatin C-values [17] (data not shown).

Primary etiologies of pediatric CKD in Japan

The primary etiologies of CKD in the study population are presented in Table 4. Non-glomerular disease (407/447; 91.1%) was the most common primary cause of CKD, whereas glomerular disease accounted for 7.8% (35/447) of all cases.

Among those with non-glomerular diseases, 278 (68.3%) children had congenital anomalies of the kidney and urinary tract (CAKUT), of which 60 (21.6% of those with CAKUT) had obstructive urological malformations comprising posterior urethral valve, stricture of the urethra, hydronephrosis, hydroureter and cloacal anomaly (Table 4). The three most common causes of glomerular diseases were Alport's syndrome, focal segmental glomerulosclerosis and chronic glomerulonephritis ($n=8$ each). No children presented with definitively diagnosed IgA nephropathy. Figure 3 shows the distribution of CAKUT and non-CAKUT diseases by age.




Fig. 1. Serum creatinine levels according to age and CKD stage. Actual serum creatinine levels according to age and CKD stage are plotted separately for males (A) and females (B).

children with other forms of CKD, particularly for analysis by chance (3.9 versus 5.8 years), urinary tract infection (0.7 versus 1.8 years) and failure to thrive (0.3 versus 2.2 years). Annual urinalysis at school detected CKD in 27 children (9.7%; median age, 8.9 years) with CAKUT and 12 children (7.1%; median age, 8.3 years) with other forms of CKD.

Treatment modalities for pediatric CKD

The treatment modalities for all patients included in this survey, and for patients with CAKUT and those with other forms of CKD, are summarized in Table 6. The most common treatments for CAKUT were angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) which were used in approximately one-quarter of the patients. Both ARBs and ACEIs together were used in 11 and 23 patients with CAKUT and other forms of CKD, respectively (data not shown). Carbon adsorbents (e.g. AST-120), which are approved as renoprotective agents adsorbing uremic toxins in the gastrointestinal tract [18] and calcium antagonists, were used in 13.0 and 7.2% of patients, respectively.

Discussion


Our findings revealed that the prevalence of stage 3–5 CKD in children in Japan aged 3 months to 15 years is 2.95 cases/100 000 children. Out of 447 CKD cases surveyed, 407 (91.1%) had non-glomerular disease; among them, 278 (68.3%) had CAKUT. To our knowledge, this is the first cross-sectional, nationwide, population-based survey of children with pre-dialysis CKD in Asia. Several reports to date have described the epidemiology of pre-dialysis CKD in children; however, these studies were restricted to Western countries [3–10].

SCr levels were frequently used to estimate the GFR and screen for CKD. The original Schwartz equation has been used extensively in clinical practice for estimating the GFR in children, where $GFR (mL/min/1.73 m^2) = \text{age-dependent coefficient } \kappa \times \text{height (cm)} / \text{SCr (mg/dL)}$ [15]. This equation was recently modified because of the increasing use of enzymatic methods to determine SCr levels, replacing the Jaffe method [17]. However, there are some possible limitations of the original Schwartz equation. First, it requires the patient's height, which is not always measured in routine clinical practice. Secondly, the GFR was reported to be lower in Asian adults than in Caucasians [19], which may have led us to overestimate the GFR when using the Schwartz equation in Asian children. To overcome these perceived limitations, several research groups have sought to establish reference levels in large populations of children [11, 20], which may be more practical and relevant for screening purposes in a specific country. Accordingly, in our present study, we evaluated renal function by comparison with established reference values [11]. In this way, CKD was determined based on SCr, rather than relying on equations adjusted for height and mathematical constants. As a result, children aged <2 years, to whom the normal CKD classification could not

The diseases included syndromal stigmata [$n=46$ (10.3%)], Down syndrome (OMIN, #190685, $n=6$), VATER association (#192350, $n=4$), Kabuki syndrome (#147920), Wolf–Hirschhorn syndrome (#194190) and Townes–Brocks syndrome (#107480, $n=3$ each), prune belly syndrome (#100100) and branchio-oto-renal syndrome (#113650, 2 each) and others.

Methods of detecting Stage 3–5 CKD

Table 5 summarizes the methods and reasons for the detection of children with stage 3–5 CKD. Table 5 also presents the age at diagnosis for each of the methods. Fetal and perinatal ultrasonography was the most common method, followed by analysis by chance and urinary tract infection. As might be expected, CKD was generally detected at an earlier age in children with CAKUT than in



Our classification	CKD classification determined using the abbreviated Schwartz equation				Total
	2	3	4	5	
Males					
3	35 (19.7%)	135 (75.8%)	8 (4.5%)	0 (0.0%)	178 (100.0%)
4	0 (0.0%)	6 (9.5%)	53 (84.1%)	4 (6.3%)	63 (100.0%)
5	0 (0.0%)	0 (0.0%)	1 (8.3%)	11 (91.7%)	12 (100.0%)
Females					
3	13 (11.2%)	99 (85.3%)	4 (3.4%)	0 (0.0%)	116 (100.0%)
4	0 (0.0%)	2 (5.7%)	30 (85.7%)	3 (8.6%)	35 (100.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)	8 (100.0%)	8 (100.0%)

Fig. 2. Distribution of CKD stage in males and females. Stage 3–5 CKD was classified using our newly established diagnostic criteria derived from normal SCr levels of age- and sex-matched Japanese children. The eGFR was determined using the abbreviated Schwartz equation [17]. Stage 3–5 CKD was classified as GFR 30–59, 15–29 and <15 mL/min/1.73 m², respectively (<1/2, <1/4 and 1/8 of normal GFR, respectively). Only subjects in whom height was measured were included in this analysis. Values in the table are *n* (%).

be applied, could be included. Similarly, Pottel *et al.* [20] proposed and validated a height-independent, population-normalized equation derived from the patient's SCr and the median SCr for age-matched healthy children. Based on their results, population-based reference levels for renal function and CKD may provide a valid approach to determine CKD stage for screening purposes, as in the present study. Indeed, our newly established CKD classification showed good validity compared with the abbreviated and complete Schwartz equations.

To classify stage 3–5 CKD, we used new diagnostic criteria based on previously determined SCr reference levels in age- and sex-matched Japanese children [11]. In that study, SCr was determined using enzymatic methods; in our current study, the participating institutes only used the enzymatic method to determine SCr. Therefore, our current results are not subject to confounding because of the use of multiple assay types.

The prevalence of pre-dialysis stage 3–5 CKD was estimated to be 2.95 cases/100 000 Japanese children, which was lower than that reported in the Italkid and REPIR II Projects (7.47 and 7.106 cases/100 000 children, respectively). The reason for this lower prevalence of CKD in Japan in comparison with Western countries is unclear, but differences in the age of the cohort and the method of case definition may account for some of the difference. For example, the Italkid Project [3] included children aged <20 years, used the original Schwartz equation to determine GFR and included children with eGFR <75 mL/min/1.73 m². Similarly, the REPIR II study [4] included children aged <19 years with stage 2 CKD, which accounted for 42% of their cases. Nevertheless, the estimated prevalence of stage 3–5 CKD in Spain, based on data from the REPIR II study, is 4.12 cases per 100 000 children (7.106 × 58%), which is slightly higher than that estimated in our study. The low frequency of pre-dialysis

Table 4. Primary etiologies of stage 3–5 chronic kidney disease in Japanese children aged 3 months to 15 years

Primary disease	Non-glomerular kidney disease (<i>n</i> = 407, 91.1%) <i>n</i> (%)	Glomerular kidney disease (<i>n</i> = 35, 7.8%) <i>n</i> (%)	Unclassified (<i>n</i> = 5, 1.1%) <i>n</i> (%)
CAKUT	278 (68.3)	0 (0.0)	0 (0.0)
CAKUT with obstructive urological malformations ^a	60 (21.6)	0 (0.0)	0 (0.0)
CAKUT without obstructive urological malformations	218 (78.4)	0 (0.0)	0 (0.0)
Cortical necrosis (perinatal period)	40 (9.8)	0 (0.0)	0 (0.0)
Polycystic kidney disease	20 (4.9)	0 (0.0)	0 (0.0)
Nephronophthisis	19 (4.7)	0 (0.0)	0 (0.0)
Drug induced	17 (4.2)	0 (0.0)	1 (20.0)
Other inherited kidney damage	10 (2.5)	1 (2.9)	0 (0.0)
Acute kidney injury	10 (2.5)	0 (0.0)	0 (0.0)
Neurogenic bladder	6 (1.5)	0 (0.0)	0 (0.0)
Other non-inheritable character	4 (1.0)	2 (5.7)	0 (0.0)
Alport's syndrome	0 (0)	8 (22.9)	0 (0.0)
Cystinosis	1 (0.2)	0 (0.0)	0 (0.0)
Wilms tumor	1 (0.2)	0 (0.0)	0 (0.0)
Chronic tubulointerstitial nephritis	1 (0.2)	0 (0.0)	0 (0.0)
Focal segmental glomerulosclerosis	0 (0.0)	8 (22.9)	0 (0.0)
Chronic glomerulonephritis	0 (0.0)	8 (22.9)	0 (0.0)
Congenital nephrotic syndrome	0 (0.0)	3 (8.6)	0 (0.0)
Hemolytic uremic syndrome	0 (0.0)	3 (8.6)	0 (0.0)
Systemic lupus erythematosus	0 (0.0)	2 (5.7)	0 (0.0)
Unknown	0 (0.0)	0 (0.0)	4 (80.0)

^aPosterior urethral valve, stricture of the urethra, hydronephrosis, hydroureter, and cloacal anomaly.

CKD in our study is consistent with the low frequency of children with ESRD in Japan [7].

A number of factors, such as differences in racial and ethnic distributions, primary cause of CKD and quality of medical care, may contribute to the difference in reported prevalence estimates between Japan and Western countries. Additionally, the prevalence of obstructive uropathy is low in Japan, being detected in just 21.6% of patients with CAKUT; by contrast, in Western countries, obstructive uropathy accounts for many cases of non-glomerular disease in children with CKD [21, 22]. Several factors may explain the differences in the prevalence of CAKUT, including (i) genetic differences that affect the distribution of obstructive diseases (e.g. prune-belly syndrome) and (ii) the diagnosis of these congenital diseases may be difficult, resulting in underestimation of obstructive uropathies. However, despite the lower frequency of obstructive uropathy in Japan, appropriate urological interventions are still an indispensable part of the management of children with CKD, because they are one of very few treatments that can change the outcome of CKD [23].

Despite the lower prevalence of CKD in our study compared with European cohorts, we believe that our data accurately represent the current situation in Japan because 1190 institutes, including all institutes belonging to the JSPN, were included in the survey and there was a very


high response rate (77.7%). We also stratified institutions by hospital type and the number of beds to improve the accuracy of the estimated prevalence. Because the response rate tended to be lower for institutions with fewer patients, estimates of CKD prevalence that do not take strata (hospital size and type) into account are possibly overestimates. For example, a simple estimate without stratification in the present study would have been 595.7 children rather than the 536.5 estimated with strata taken into account. Thus, the stratified estimation method should correct for a bias between response rates and hospital type/size. Nevertheless, it is possible that some patients with stage 3–5 CKD were treated at other types of institutions not included in this survey.

The majority of Japanese children with CKD presented with non-glomerular disease. CAKUT was the primary cause of CKD (i.e. 62.2% of all CKD cases). This observation was expected. Unlike in adults, in whom diabetes and hypertension are the primary cause of CKD, congenital causes are responsible for majority of pediatric CKD cases [1, 7]. The prevalence of CAKUT in our study is also consistent with that reported in the ItalKid and REPIR II studies (67.5 and 59%, respectively) [3, 4].

Interestingly, there were very few cases of glomerular disease, such as focal segmental glomerulosclerosis, and no confirmed cases of IgA nephropathy (one case was suspected, but diagnosis was not confirmed). In a Japanese registry of pediatric ESRD patients conducted in 1998, 19% of patients had focal segmental glomerulosclerosis and 3% had IgA nephropathy [24]. The present analysis is likely to have underestimated the prevalence of these diseases for several reasons. First, these diseases progress more rapidly than non-glomerular diseases and could have been missed in the survey. Secondly, we restricted our analysis to those aged <16 years, but chronic glomerulonephritis frequently affects patients aged 16–20 years. Furthermore, these diseases respond well to novel treatment regimens that are well established in Japan, including combination therapy for IgA nephropathy [25] and cyclosporine in combination with steroids for steroid-resistant nephrotic syndrome, including focal segmental glomerulosclerosis [26].

Fetal/neonatal ultrasonography was the most frequently used method to detect CAKUT, followed by blood analyses by chance and investigation of urinary tract infection. Only 27 children with CAKUT and 12 with other forms of CKD were detected following annual urinalysis at school. Patients with CKD, particularly children with CAKUT, do not necessarily show abnormal urinalysis, and are missed by the screening. It is also possible that CKD (particularly non-CAKUT forms of CKD) could be detected in the earlier stages (earlier than stage 3) and patients could then receive appropriate intervention to treat the underlying disease. The treatment strategies for CAKUT and other forms of CKD were generally similar (Table 6), although the responding institutions more often reported using carbon absorbents for CAKUT and ACEIs in other forms of CKD (data not shown).

Some limitations of the study merit consideration. First, only 77.7% of the surveyed institutions responded to the questionnaire, which may limit the accuracy of the



Age	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	Total
Population (thousands) ^a	1,676	1,692	1,694	1,672	1,659	1,655	1,111	1,145	1,160	1,189	1,179	1,193	1,188	1,183	1,206	1,208	18,217
CAKUT ^b	15	24	13	13	15	13	13	28	20	11	23	20	21	15	15	39	278
Other forms of CKD ^b	4	5	9	5	8	11	9	12	12	15	10	15	14	12	12	16	169

Fig. 3. Age distribution of children with stage 3–5 CKD in Japan. Children with CAKUT are shown in red bars, while those with other forms of CKD are shown in blue bars. Total numbers of children of each age in Japan derived from national census data (1 April 2010) published by the Statistics Bureau of Ministry of Internal Affairs and Communications in Japan (<http://www.stat.go.jp/english/index.htm>)^a. Number of children with CAKUT or other forms of CKD reported in the survey^b.

Table 5. Method of detection of Stage 3–5 CKD

Screening method	CAKUT (<i>n</i> = 278)	Other forms of CKD (<i>n</i> = 169)		Other forms of CKD (<i>n</i> = 169)	Age at which CKD was detected (years)	
	<i>n</i> (%)	Median	IQR	<i>n</i> (%)	Median	IQR
Fetal ultrasonography/ultrasonography in the neonatal period	88 (31.7)	0.0	0.0–0.0	19 (11.2)	0.0	0.0–0.0
Analysis by chance	38 (13.7)	3.9	1.2–6.1	32 (18.9)	5.8	1.7–9.4
Urinary tract infection	38 (13.7)	0.7	0.3–2.0	4 (2.4)	1.8	0.3–3.6
Annual urinalysis at school	27 (9.7)	8.9	7.0–10.3	12 (7.1)	8.3	7.1–10.9
Blood analysis in the neonatal period, asphyxia, neonatal shock and other events	25 (9.0)	0.0	0.0–0.1	31 (18.3)	0.0	0.0–0.0
Failure to thrive, weight loss and general fatigue	25 (9.0)	0.3	0.1–1.0	7 (4.1)	2.2	0.2–12.3
Urinalysis at 3 years	9 (3.2)	3.2	3.0–3.4	7 (4.1)	3.1	3.0–3.6
Routine health check (infants/toddlers)	7 (2.5)	0.3	0.1–1.7	4 (2.4)	2.8	0.4–5.1
Symptoms of glomerulonephritis (edema, oliguria or gross hematuria)	5 (1.8)	3.8	1.0–5.0	13 (7.7)	5.3	2.7–8.7
Analysis because of anomalies and syndromal stigmata	3 (1.1)	0.0	0.0–0.1	1 (0.6)	1.7	1.7–1.7
Detected during the management of other diseases (e.g. heart disease and malignancy)	2 (0.7)	5.3	5.3–5.3	18 (10.7)	3.2	0.2–8.2
Dysuria, including neurogenic bladder and nocturia	2 (0.7)	4.9	4.9–4.9	4 (2.4)	5.7	1.2–9.5
Analysis because of family history	0 (0.0)	—	—	3 (1.8)	6.2	4.5–9.7
Sepsis	0 (0.0)	—	—	3 (1.8)	0.0	0.0–0.1
Others	0 (0.0)	—	—	2 (1.2)	2.2	0.8–3.7
Unknown (not available)	9 (3.2)	—	—	9 (5.3)	—	—

CKD, chronic kidney disease; CAKUT, congenital anomalies of the kidney and urinary tract.

Table 6. Treatment strategies for CAKUT and other forms of CKD for individual patients

	CAKUT (<i>n</i> = 278) <i>n</i> (%)	Other forms of CKD (<i>n</i> = 169) <i>n</i> (%)	All patients (<i>n</i> = 447) <i>n</i> (%)
ARBs			
No	201 (72.3)	115 (68.0)	316 (70.7)
Yes	74 (26.6)	53 (31.4)	127 (28.4)
NA	3 (1.1)	1 (0.6)	4 (0.9)
ACEIs			
No	209 (75.2)	108 (63.9)	317 (70.9)
Yes	66 (23.7)	60 (35.5)	126 (28.2)
NA	3 (1.1)	1 (0.6)	4 (0.9)
Carbon absorbents			
No	237 (85.3)	144 (85.2)	381 (85.2)
Yes	34 (12.2)	24 (14.2)	58 (13.0)
NA	7 (2.5)	1 (0.6)	8 (1.8)
Calcium antagonists			
No	264 (94.9)	147 (87.0)	411 (91.9)
Yes	11 (4.0)	21 (12.4)	32 (7.2)
NA	3 (1.1)	1 (0.6)	4 (0.9)

CAKUT, congenital anomalies of the kidney and urinary tract; CKD, chronic kidney disease; ARB, angiotensin II receptor blocker; ACEI, angiotensin-converting enzyme inhibitor; NA, not available.

430 estimate. Secondly, although the classification system used
for CKD staging in the present study was based on refer-
ence SCr levels determined via enzymatic methods from
Japanese children, these diagnostic criteria have not been
435 validated globally and reference values would be needed
for other populations. Height could have also been deter-
mined to estimate GFR via the Schwartz equation;
however, because the GFR is inversely proportional to
SCr in age- and sex-matched individuals, and because we
440 used age- and sex-matched reference SCr levels estab-
lished in a previous study with 1151 children, our
measurements should be accurate enough and more practi-
cal for screening purposes. Indeed, our CKD staging
showed good agreement with CKD staging based on the
abbreviated Schwartz equation (Figure 2). Because, our
445 CKD staging method is based on the SCr level, CKD may
be missed in children with small muscle mass, such as
those with spina bifida, neuromuscular disease and short
stature.

To our knowledge, this is the first nationwide, popu-
450 lation-based survey of children with pre-dialysis CKD in
Asia and applied reference levels for CKD derived from a
large cohort of Japanese children. This method showed
good agreement with the abbreviated Schwartz equation
and is practical for screening purposes, including children
455 aged <2 years, as current methods are not appropriate for
estimating CKD in this age group. The estimated preva-
lence of stage 3–5 CKD in Japan was 2.95 cases/100 000
children, which is lower than that in Western countries.
Most cases presented with non-glomerular disease, and
460 CAKUT was the most common cause of CKD. Improved
management of CAKUT in children with CKD, including
renoprotective treatment and urological interventions, is
required. We are planning randomized and longitudinal
studies to improve the management of pediatric CKD, and
465 better understand its long-term prognosis.

Acknowledgements. This work was supported by the ‘Research on rare and intractable diseases, Health and Labour Sciences Research Grants’ from the Ministry of Health, Labour and Welfare in Japan. The authors would like to thank Drs Takuhito Nagai (Aichi), Kenichi Satomura (Osaka), Midori Awazu (Tokyo), Toshiyuki Ohta (Hiroshima), Kazumoto Iijima (Hyogo), Takeshi Matsuyama (Tokyo), Mayumi Sako (Tokyo), Hidefumi Nakamura (Tokyo), Shuichiro Fujinaga (Saitama), Hiroshi Kitayama (Shizuoka), Naoya Fujita (Shizuoka), Masataka Hisano (Chiba), Yuko Akioka (Tokyo), Daishi Hirano (Tokyo), Hiroshi Hataya (Tokyo), Yoshinobu Nagaoka (Tokyo), Takashi Sekine (Tokyo), Yoshimitsu Goto (Aichi), Takuji Yamada (Aichi), Yohei Ikezumi (Niigata), Takeshi Yamada (Niigata) and Akira Matsunaga (Yamagata) of The Pediatric CKD Study Group in Japan for their contributions to the study. The authors also would like to thank the institutions listed in the Supplementary Material for their participation in surveys. The results presented in this paper have not been published previously in whole or part, except in abstract format.

Conflict of interest statement. None declared.

References

- Warady BA, Chadha V. Chronic kidney disease in children: the global perspective. *Pediatr Nephrol* 2007; 22: 1999–2009. 485
- McDonald SP, Craig JC. Long-term survival of children with end-stage renal disease. *New Engl J Med* 2004; 350: 2654–2662.
- Ardissino G, Dacco V, Testa S *et al.* Epidemiology of chronic renal failure in children: data from the ItalKid project. *Pediatrics* 2003; 111: e382–387. 490
- Areses Trapote R, Sanahuja Ibanez MJ, Navarro M. Epidemiology of chronic kidney disease in Spanish pediatric population. REPIR II Project. *Nefrologia* 2010; 30: 508–517 (in Spanish).
- Esbjorner E, Berg U, Hansson S. Epidemiology of chronic renal failure in children: a report from Sweden 1986–1994. Swedish Pediatric Nephrology Association. *Pediatr Nephrol* 1997; 11: 438–442. 495
- Furth SL, Cole SR, Moxey-Mims M *et al.* Design and methods of the chronic kidney disease in children (CKiD) prospective cohort study. *Clin J Am Soc Nephrol* 2006; 1: 1006–1015. 500
- Harambat J, van Stralen KJ, Kim JJ *et al.* Epidemiology of chronic kidney disease in children. *Pediatr Nephrol*. 2011; 27: 363–373.
- Mong Hiep TT, Ismaili K, Collart F *et al.* Clinical characteristics and outcomes of children with stage 3–5 chronic kidney disease. *Pediatr Nephrol* 2010; 25: 935–940. 505
- Deleau J, Andre JL, Briancon S *et al.* Chronic renal failure in children: an epidemiological survey in Lorraine (France) 1975–1990. *Pediatr Nephrol* 1994; 8: 472–476.
- US Renal Data System. 2010 Atlas of CKD & ESRD; 2010.
- Uemura O, Honda M, Matsuyama T *et al.* Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study. *Clin Exp Nephrol* 2011; 15: 694–6990. 510
- K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002; 39(2 Suppl 1): S1–S266. 515
- Hogg RJ, Furth S, Lemley KV *et al.* National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. *Pediatrics* 2003; 111: 1416–1421. 520
- Levey AS, Eckardt KU, Tsukamoto Y *et al.* Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2005; 67: 2089–2100.
- Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. *Pediatr Clin North Am* 1987; 34: 571–590. 525
- Hashimoto S, Fukutomi K, Nagai M *et al.* A note on methods for estimating the number of patients in the nationwide epidemiological survey on intractable diseases. *Nihon Koshu Eisei Zasshi* 1990; 37: 768–774 (in Japanese). 530

17. Schwartz GJ, Munoz A, Schneider MF *et al.* New equations to estimate GFR in children with CKD. *J Am Soc Nephrol* 2009; 20: 629–637.
- 535 18. Akizawa T, Asano Y, Morita S *et al.* Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. *Am J Kidney Dis* 2009; 54: 459–467.
19. Imai E, Horio M, Nitta K *et al.* Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. *Clin Exp Nephrol* 2007; 11: 41–50.
- 540 20. Pottel H, Hoste L, Martens F. A simple height-independent equation for estimating glomerular filtration rate in children. *Pediatr Nephrol* 2012; 27: 973–979.
21. Chadha V, Warady BA. Epidemiology of pediatric chronic kidney disease. *Adv Chronic Kidney Dis* 2005; 12: 343–352.
- 545 22. Furth SL, Abraham AG, Jerry-Fluker J *et al.* Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease. *Clin J Amer Soc Nephrol* 2011; 6: 2132–2140.
23. Nakai N, Asanuma H, Shishido S *et al.* Changing concepts in urological management of the congenital abnormalities of kidney and urinary tract, CAKUT. *Pediatr Int* 2003; 45: 634–641. 550
24. Hattori S, Yosioka K, Honda M *et al.* The 1998 report of the Japanese National Registry data on pediatric end-stage renal disease patients. *Pediatr Nephrol* 2002; 17: 456–461. 555
25. Kamei K, Nakanishi K, Ito S *et al.* Long-term results of a randomized controlled trial in childhood IgA nephropathy. *Clin J Am Soc Nephrol* 2011; 6: 1301–1307.
26. Hamasaki Y, Yoshikawa N, Hattori S *et al.* Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. *Pediatr Nephrol* 2009; 24: 2177–2185. 560

Received for publication: 23.8.12; Accepted in revised form: 18.12.12